Biotechnology

Disc Medicine

Today’s Key News Recap

INTC

02423

IRON

300024

INTE

01698

09888

09868

02525

HSAI

OpenAI

DXYZ

BEKE

BIDU

89888

XPEV

04335

MS-A

MS-E

MS-F

MS-I

MS-K

MS-L

MS-O

MS-P

MS-Q

INTEU

INTEW

HBUD

<p>1111 ｜Dolphin Research Key Focus: 🐬 Macro/Industry 1. The U.S. Senate has passed a temporary spending bill aimed at ending the longest government shutdown in history, which has lasted for 41 days. The bill now requires approval from the House of Representatives and the President's signature to take effect. This move is a result of bipartisan compromise, providing short-term relief from economic and livelihood impacts, but the core disagreements are merely postponed, with the possibility of another deadlock after January 30th, highlighting the increasing trend of political polarization in the United States. 🐬 Individual Stocks 1. <span class="security-tag" type="security-tag" counter_id="ST/US/BIDU" name="Baidu" trend="">$Baidu(BIDU.US)</span> RoboTaxi has received the first batch of fully unmanned commercial operation licenses issued by the Abu Dhabi Integrated Transport Center...</p>

Intel

BEKE-W

SIASUN

Morgan Stanley

Integra Group (Russia) Sponsored GDR RegS

Integral Acquisition  1

TME-SW

BIDU-SW

XPENG-W

HESAI-W

Hesai

Destiny Tech100

Citigroup

Tencent Music

Baidu

BIDU-SWR

XPeng

INTEL-T

BTQ Tech

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

Integral Acquisition 1 - Unit

INTEGRAL ACQUISITION CORP 1 C/WTS 31/05/2028 (TO PUR COM)

Baidu HK SDR 10to1

XPeng surged 17% in a single day; Intel AI Chief jumps ship to OpenAI | Today's Important News Recap

Disc Medicine Inc.'s CMO Sells Company's Common Stock

Disc Medicine reports Bitopertin NDA approval and expected launch at ASH Annual Meeting

Disc Medicine Inc. Announces Positive Results from DISC-0974 Clinical Trial

Ensign Peak Advisors Inc Significantly Increased Holdings in Disc Medicine

Disc Medicine Initiates Clinical Trial for Sickle Cell Disease Treatment and Receives FDA Priority Review for Bitopertin

H.C. Wainwright Analyst Maintains Buy Rating for Disc Medicine

Truist Analyst Reiterates Buy Rating on Disc Medicine with $114 Price Target

Disc Medicine released FY2025 9 Months Earnings on November 6 (EST), actual revenue USD 0, actual EPS USD -4.3717

Disc Medicine released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.7715 (forecast USD -1.4709)

Disc Medicine reports Q3 2025 financials and future product pipeline outlook

Disc Medicine Inc. reports Q3 2025 earnings and submits new drug application

Disc Medicine Inc. to Present Preliminary Data from Two Drug Trials at ASH Annual Meeting

AI DMI LLC reported the disposition of common stock of Disc Medicine Inc.

Disc Medicine Announces $210.9 Million Stock Offering

Disc Medicine Inc. Launches $220 Million Underwritten Public Offering

Disc Medicine Inc. Submits New Drug Application for Bitopertin and Hits 52-Week High